OBJECTIVE: The aim of the present work was to investigate the clinical efficacy of first-line chemotherapy regimens in the treatment of advanced non-small cell lung cancer (NSCLC) through a comprehensive network meta-analysis (NMA). METHODS: The prospective randomized controlled clinical trials relevant to 10 first-line chemotherapy regimens in the treatment of advanced NSCLC were systematic electronic search in the databases of Pubmed, Embase, Cochrane Library and CNKI. The combined direct or indirect objective response rate (ORR) between each of the 10 first-line chemotherapy regimens was calculated. RESULTS: Seventeen prospective clinical trials of first-line chemotherapy regimens in treatment of advanced NSCLC were included in the NMA. The 10 treatment regimens including A = cisplatin + gemcitabine, B = carboplatin + gemcitabine, C = gemcitabine, D = carboplatin + paclitaxel, E = paclitaxel + gemcitabine, F = docetaxel + carboplatin, G = gemcitabine + vinorelbine, H = pemetrexed + carboplatin, I = cisplatin + pemetrexed and J = cisplatin + docetaxel were compared in the present NMA. Direct pooled results indicated that the ORR was not statistically different (P all > 0.05). However, NMA showed that the combined ORR for regimens A (OR = 1.47, 95% CI: 0.80-2.81), B (OR = 3.22, 95% CI: 1.45-6.923), D (OR = 3.30, 95% CI: 1.22-9.33), E (OR = 4.36, 95% CI: 1.64-12.82), G (OR = 3.72, 95% CI: 1.12-12.83) and I (OR = 5.80, 95% CI: 2.04-17.86) was superior to regimen C. Rank probability analysis indicated that regimen C = gemcitabine and regimen I = cisplatin + pemetrexed had the highest probability of inferior and superior treatment ORR among the 10 first-line chemotherapy regimens. CONCLUSION: Cisplatin + pemetrexed may have particularly prominent ORR for advanced NSCLC as the first-line chemotherapy regimen.
OBJECTIVE: The aim of the present work was to investigate the clinical efficacy of first-line chemotherapy regimens in the treatment of advanced non-small cell lung cancer (NSCLC) through a comprehensive network meta-analysis (NMA). METHODS: The prospective randomized controlled clinical trials relevant to 10 first-line chemotherapy regimens in the treatment of advanced NSCLC were systematic electronic search in the databases of Pubmed, Embase, Cochrane Library and CNKI. The combined direct or indirect objective response rate (ORR) between each of the 10 first-line chemotherapy regimens was calculated. RESULTS: Seventeen prospective clinical trials of first-line chemotherapy regimens in treatment of advanced NSCLC were included in the NMA. The 10 treatment regimens including A = cisplatin + gemcitabine, B = carboplatin + gemcitabine, C = gemcitabine, D = carboplatin + paclitaxel, E = paclitaxel + gemcitabine, F = docetaxel + carboplatin, G = gemcitabine + vinorelbine, H = pemetrexed + carboplatin, I = cisplatin + pemetrexed and J = cisplatin + docetaxel were compared in the present NMA. Direct pooled results indicated that the ORR was not statistically different (P all > 0.05). However, NMA showed that the combined ORR for regimens A (OR = 1.47, 95% CI: 0.80-2.81), B (OR = 3.22, 95% CI: 1.45-6.923), D (OR = 3.30, 95% CI: 1.22-9.33), E (OR = 4.36, 95% CI: 1.64-12.82), G (OR = 3.72, 95% CI: 1.12-12.83) and I (OR = 5.80, 95% CI: 2.04-17.86) was superior to regimen C. Rank probability analysis indicated that regimen C = gemcitabine and regimen I = cisplatin + pemetrexed had the highest probability of inferior and superior treatment ORR among the 10 first-line chemotherapy regimens. CONCLUSION: Cisplatin + pemetrexed may have particularly prominent ORR for advanced NSCLC as the first-line chemotherapy regimen.
Authors: Frank Griesinger; Ellen E Korol; Sheena Kayaniyil; Nebibe Varol; Timo Ebner; Sarah M Goring Journal: Lung Cancer Date: 2019-07-13 Impact factor: 5.705
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Corey Langer; Sigui Li; Joan Schiller; William Tester; Bernardo L Rapoport; David H Johnson Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: T Le Chevalier; G Scagliotti; R Natale; S Danson; R Rosell; R Stahel; P Thomas; R M Rudd; J Vansteenkiste; N Thatcher; C Manegold; J-L Pujol; N van Zandwijk; C Gridelli; J P van Meerbeeck; L Crino; A Brown; P Fitzgerald; M Aristides; J H Schiller Journal: Lung Cancer Date: 2005-01 Impact factor: 5.705
Authors: Mark A Socinski; Robert N Raju; Thomas Stinchcombe; Darren M Kocs; Linda S Couch; David Barrera; Steven R Rousey; Janak K Choksi; Robert Jotte; Debra A Patt; Phillip O Periman; Howard R Schlossberg; Charles H Weissman; Yunfei Wang; Lina Asmar; Sharon Pritchard; Jane Bromund; Guangbin Peng; Joseph Treat; Coleman K Obasaju Journal: J Thorac Oncol Date: 2010-12 Impact factor: 15.609
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544